NCI Trial Identifier,Lead Organization,Lead Org PO ID,Processing Priority,CTEP ID,DCP ID,Official Title,Milestone,Admin Milestone,Scientific Milestone,Processing Status,Processing Status Date,Trial Type,Trial Sub-type,Record Verification Date,Onhold Reasons,Onhold Dates,Submission Type,Submission Source,Checked Out for Admin. Use by,Checked Out for Scientific Use by
NCI-2019-02588,Bayer Corporation,35145,2,,,"An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Tumor Response Profile of the Anti-CEACAM6 Antibody BAY1834942 in Patients With Advanced Solid Tumors","Initial Abstraction Verified Date
                04/29/2019",,,Abstraction Verified Response,04/29/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-02318,Sermonix Pharmaceuticals LLC,88752237,2,,,"An Open-Label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2? Breast Cancer With an ESR1 Mutation","Initial Abstraction Verified Date
                04/20/2019",,,Abstraction Verified No Response,04/20/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-02123,Rain Therapeutics Inc.,88648266,2,,,A Phase 2 Study to Evaluate the Objective Response to Tarloxotinib Administered Intravenously to Patients With Non Small Cell Lung Cancer That Harbors Either EGFR Exon 20 Insertion or a HER2-Activating Mutation,"Initial Abstraction Verified Date
                04/16/2019",,,Abstraction Verified No Response,04/16/2019,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-02082,Novartis Pharmaceuticals Corporation,170150,2,,,Managed Access Program (MAP) to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer Resistant or Refractory to Available Treatment Options,"Initial Abstraction Verified Date
                04/13/2019",,,Abstraction Verified No Response,04/13/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01822,AstraZeneca Pharmaceuticals LP,34899,2,,,"A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)","Initial Abstraction Verified Date
                04/03/2019",,,Abstraction Verified No Response,04/03/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01819,University of Florida Health Science Center - Gainesville,70710,2,,,"A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma","Initial Abstraction Verified Date
                04/04/2019",,,Abstraction Verified No Response,04/04/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01725,Incyte Corporation,109566,2,,,"A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)","Initial Abstraction Verified Date
                03/28/2019",,,Abstraction Verified No Response,03/28/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01692,Fate Therapeutics,70024,2,,,FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1),"Initial Abstraction Verified Date
                03/28/2019",,,Abstraction Verified No Response,03/28/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01685,UroGen Pharma Ltd.,51684763,2,,,"A Phase 2b, Single-Arm, Multicenter Trial to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC) at Intermediate Risk of Recurrence","Initial Abstraction Verified Date
                03/28/2019",,,Abstraction Verified No Response,03/28/2019,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01629,Merck and Company Inc,147288,2,,,"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)","Initial Abstraction Verified Date
                03/26/2019",,,Abstraction Verified No Response,03/26/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01628,"PellePharm, Inc.",88351981,2,,,"A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome","Initial Abstraction Verified Date
                03/26/2019",,,Abstraction Verified No Response,03/26/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01597,Merck and Company Inc,147288,2,,,"A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782)","Initial Abstraction Verified Date
                03/26/2019",,,Abstraction Verified No Response,03/26/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01553,National Cancer Institute,154376,2,,,A Phase II Study of Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18F-DCFPyL-PET/CT in Newly Diagnosed Prostate Cancer,"Initial Abstraction Verified Date
                03/22/2019",,,Abstraction Verified No Response,03/22/2019,Interventional,,04/18/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01529,AstraZeneca Pharmaceuticals LP,34899,2,,,"Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies","Initial Abstraction Verified Date
                03/21/2019",,,Abstraction Verified No Response,03/21/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01527,"Astellas Pharma Global Development, Inc.",48002713,2,,,"A Phase 2, Open-Label, Single-Arm, Multicenter Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors","Initial Abstraction Verified Date
                03/21/2019",,,Abstraction Verified No Response,03/21/2019,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01524,NovImmune SA,46085785,2,,,"An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFN?) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis","Initial Abstraction Verified Date
                03/21/2019",,,Abstraction Verified No Response,03/21/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01497,Pfizer,41749415,2,,,"A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE","Initial Abstraction Verified Date
                03/20/2019",,,Abstraction Verified No Response,03/20/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01456,"Radius Pharmaceuticals, Inc.",53497247,2,,,"Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial","Initial Abstraction Verified Date
                03/19/2019",,,Abstraction Verified No Response,03/19/2019,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01432,Novartis Pharmaceuticals Corporation,170150,2,,,"A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.","Initial Abstraction Verified Date
                03/16/2019",,,Abstraction Verified No Response,03/16/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01429,Agios Pharmaceuticals,11722315,2,,,A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma,"Initial Abstraction Verified Date
                03/16/2019",,,Abstraction Verified No Response,03/16/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01395,Torque Therapeutics Inc,88175379,2,,,A Phase 1/1b Open-Label Multi-Center Study to Characterize the Safety and Tolerability of TRQ15-01 in Patients With Relapsed/Refractory Solid Tumors and Lymphomas,"Initial Abstraction Verified Date
                03/15/2019",,,Abstraction Verified No Response,03/15/2019,Interventional,,02/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01390,AstraZeneca Pharmaceuticals LP,34899,2,,,"A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)","Initial Abstraction Verified Date
                03/14/2019",,,Abstraction Verified No Response,03/14/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01289,"Turnstone Biologics, Inc.",88060811,2,,,"Phase 1/1b, Multicenter, Open-label Trial of Oncolytic MG1 Virus (MG1-E6E7) With Adenovirus Vaccine (Ad-E6E7) Both Expressing Mutant Human Papilloma Virus (HPV) E6 and E7 and Atezolizumab in Pts With HPV Assoc. Cancers","Initial Abstraction Verified Date
                03/12/2019",,,Abstraction Verified No Response,03/12/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01263,VelosBio Inc.,88057329,2,,,A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS -101 in Subjects With Hematological Malignancies,"Initial Abstraction Verified Date
                03/12/2019",,,Abstraction Verified No Response,03/12/2019,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-01196,National Cancer Institute,154376,2,,,Natural History Study of Men at High Genetic Risk for Prostate Cancer,"Initial Abstraction Verified Date
                03/09/2019",,,Abstraction Verified No Response,03/09/2019,Non-interventional,Observational,03/04/2019,,,U,ClinicalTrials.gov,,
NCI-2019-00860,PTC Therapeutics,60042984,2,,,Phase 1b Study of PTC299 in Relapsed/Refractory Acute Leukemias,"Initial Abstraction Verified Date
                02/23/2019",,,Abstraction Verified No Response,02/23/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-00762,Deciphera Pharmaceuticals LLC,67743,2,,,"An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors","Initial Abstraction Verified Date
                02/20/2019",,,Abstraction Verified No Response,02/20/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-00663,Incyte Corporation,109566,2,,,"A Phase 1, Open-Label, Dose-Finding Study of Parsaclisib in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)","Initial Abstraction Verified Date
                02/15/2019",,,Abstraction Verified No Response,02/15/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-00599,"Fujifilm Pharmaceuticals U.S.A., Inc.",43161701,2,,,A Phase 1 Dose-escalation Study of FF 10832 for the Treatment of Advanced Solid Tumors,"Initial Abstraction Verified Date
                02/12/2019",,,Abstraction Verified No Response,02/12/2019,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2019-00303,National Cancer Institute,154376,2,,,"A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer","Initial Abstraction Verified Date
                01/23/2019",,,Abstraction Verified No Response,01/23/2019,Interventional,,04/10/2019,,,U,ClinicalTrials.gov,,
NCI-2019-00301,National Cancer Institute,154376,2,,,Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease With Laboratory and Clinical Correlates of Disease Activity,"Initial Abstraction Verified Date
                01/23/2019",,,Abstraction Verified No Response,01/23/2019,Interventional,,04/16/2019,,,U,ClinicalTrials.gov,,
NCI-2019-00300,National Cancer Institute,154376,2,,,Randomized Trial of Cladribine (CdA) With Simultaneous or Delayed Rituximab to Eliminate Hairy Cell Leukemia Minimal Residual Disease,"Initial Abstraction Verified Date
                01/23/2019",,,Abstraction Verified No Response,01/23/2019,Interventional,,03/18/2019,,,U,ClinicalTrials.gov,,
NCI-2019-00041,National Cancer Institute,154376,2,,,"Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases","Initial Abstraction Verified Date
                01/18/2019",,,Abstraction Verified No Response,01/18/2019,Interventional,,04/18/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03783,Eli Lilly and Company,119479,2,,,A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%),"Initial Abstraction Verified Date
                01/15/2019",,,Abstraction Verified No Response,01/15/2019,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03689,National Cancer Institute,154376,2,,,Safety Run-In and Phase II Trial of M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers,"Initial Abstraction Verified Date
                01/10/2019",,,Abstraction Verified No Response,01/10/2019,Interventional,,04/11/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03688,National Cancer Institute,154376,2,,,"A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in Patients With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment","Initial Abstraction Verified Date
                01/10/2019",,,Abstraction Verified No Response,01/10/2019,Interventional,,04/18/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03685,National Cancer Institute,154376,2,,,"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1)","Initial Abstraction Verified Date
                01/10/2019",,,Abstraction Verified No Response,01/10/2019,Interventional,,04/05/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03593,National Cancer Institute,154376,2,,,Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer,"Initial Abstraction Verified Date
                01/04/2019",,,Abstraction Verified No Response,01/04/2019,Interventional,,04/19/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03584,National Cancer Institute,154376,2,,,Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas,"Initial Abstraction Verified Date
                01/01/2019",,,Abstraction Verified No Response,01/01/2019,Interventional,,04/16/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03458,National Cancer Institute,154376,2,,,Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma,"Initial Abstraction Verified Date
                12/28/2018",,,Abstraction Verified No Response,12/28/2018,Interventional,,04/15/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03421,Immunomedics Inc,104971,2,,,"Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy","Initial Abstraction Verified Date
                12/26/2018",,,Abstraction Verified No Response,12/26/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03368,National Cancer Institute,154376,2,,,"Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer","Initial Abstraction Verified Date
                12/15/2018",,,Abstraction Verified No Response,12/15/2018,Interventional,,03/15/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03364,National Cancer Institute,154376,2,,,Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer,"Initial Abstraction Verified Date
                12/14/2018",,,Abstraction Verified No Response,12/14/2018,Interventional,,04/10/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03333,National Cancer Institute,154376,2,,,"A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment With Osimertinib (AZD9291, Tagrisso)","Initial Abstraction Verified Date
                12/13/2018",,,Abstraction Verified No Response,12/13/2018,Interventional,,03/22/2019,,,U,ClinicalTrials.gov,,
NCI-2018-03288,Blaze Bioscience Inc.,49121491,2,,,"A Randomized, Blinded Study of Fluorescence Detection of Pediatric Primary Central Nervous System Tumors in Subjects Receiving Tozuleristide and Imaged With the Canvas System","Initial Abstraction Verified Date
                12/20/2018",,,Abstraction Verified No Response,12/20/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-02925,Novartis Pharmaceuticals Corporation,170150,2,,,"Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)","Initial Abstraction Verified Date
                12/06/2018",,,Abstraction Verified No Response,12/06/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-02730,National Cancer Institute,154376,2,,,"Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma","Initial Abstraction Verified Date
                11/28/2018",,,Abstraction Verified No Response,11/28/2018,Interventional,,04/26/2019,,,U,ClinicalTrials.gov,,
NCI-2018-02725,National Cancer Institute,154376,2,,,"Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers","Initial Abstraction Verified Date
                11/28/2018",,,Abstraction Verified No Response,11/28/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-02693,National Cancer Institute,154376,2,,,"Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors","Initial Abstraction Verified Date
                11/27/2018",,,Abstraction Verified No Response,11/27/2018,Non-interventional,Observational,03/18/2019,,,U,ClinicalTrials.gov,,
NCI-2018-02362,"Sorrento Therapeutics, Inc.",59207694,2,,,"A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma","Initial Abstraction Verified Date
                11/02/2018",,,Abstraction Verified No Response,11/02/2018,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-02189,National Cancer Institute,154376,2,,,A Comparative Study of Pediatric CNS Tumor Activity as Assessed by [18]F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging ([1]H-MRSI),"Initial Abstraction Verified Date
                10/11/2018",,,Abstraction Verified No Response,10/11/2018,Non-interventional,Observational,04/17/2019,,,U,ClinicalTrials.gov,,
NCI-2018-02045,BTG International Inc,25956178,2,,,RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry,"Initial Abstraction Verified Date
                10/03/2018",,,Abstraction Verified No Response,10/03/2018,Non-interventional,Observational,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-01995,Vascular Biogenics,242384,2,,,"A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer","Initial Abstraction Verified Date
                09/27/2018",,,Abstraction Verified No Response,09/27/2018,Interventional,,01/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-01847,Cambium Medical Technologies LLC,64118410,2,,,Randomized Multicenter Double-Masked Placebo-Controlled Parallel Phase I/II Study to Determine the Safety and Exploratory Efficacy of Topical Fibrinogen Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs Host Disease,"Initial Abstraction Verified Date
                09/08/2018",,,Abstraction Verified No Response,09/08/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-01787,NYP/Weill Cornell Medical Center,170710,2,,,A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA),"Initial Abstraction Verified Date
                09/05/2018",,,Abstraction Verified No Response,09/05/2018,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-01729,"Janssen Research & Development, LLC",48659622,2,,,"An Open-label, Multicenter, Phase 1b Study of JNJ-63723283, a PD-1 Inhibitor, Administered in Combination With Apalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer","Initial Abstraction Verified Date
                08/29/2018",,,Abstraction Verified No Response,08/29/2018,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-01620,"Rgenix, Inc.",52769298,2,,,"A Phase 1 Study of RGX-202-01, a Small Molecule Inhibitor of the Creatine Transporter SLC6a8, With or Without FOLFIRI, in Patients With Advanced Gastrointestinal Malignancies With Select Expansion Cohorts","Initial Abstraction Verified Date
                08/04/2018",,,Abstraction Verified No Response,08/04/2018,Interventional,,07/01/2018,,,U,ClinicalTrials.gov,,
NCI-2018-01378,Merck and Company Inc,147288,2,,,"A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)","Initial Abstraction Verified Date
                07/11/2018",,,Abstraction Verified No Response,07/11/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-01252,Global Blood Therapeutics,53400018,2,,,"A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease","Initial Abstraction Verified Date
                06/27/2018",,,Abstraction Verified No Response,06/27/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00967,Ethicon Endo-Surgery,53684753,2,,,"A Prospective, Multi-Center Evaluation of the ECHELON CIRCULAR Powered Stapler in Left-Sided Colorectal Anastomoses","Initial Abstraction Verified Date
                05/31/2018",,,Abstraction Verified No Response,05/31/2018,Non-interventional,Observational,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00817,"Daiichi Sankyo Co., Ltd.",48439150,2,,,"A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Colorectal Cancer","Initial Abstraction Verified Date
                05/16/2018",,,Abstraction Verified No Response,05/16/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00676,Seattle Genetics,219916,2,,,Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors,"Initial Abstraction Verified Date
                05/01/2018",,,Abstraction Verified No Response,05/01/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00646,"Advaxis, Inc.",48659730,2,,,"A Phase 1 Dose-Escalation Study of ADXS NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors","Initial Abstraction Verified Date
                05/01/2018",,,Abstraction Verified No Response,05/01/2018,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00598,"Boston Biomedical, Inc",35175,2,,,A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid Tumors,"Initial Abstraction Verified Date
                04/18/2018",,,Abstraction Verified No Response,04/18/2018,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00569,AstraZeneca Pharmaceuticals LP,34899,2,,,"An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).","Initial Abstraction Verified Date
                04/14/2018",,,Abstraction Verified No Response,04/14/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00367,"Janssen Research & Development, LLC",48659622,2,,,"A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564, a Humanized DuoBody® Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma","Initial Abstraction Verified Date
                03/15/2018",,,Abstraction Verified No Response,03/15/2018,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00366,Hoffmann-La Roche,90971,2,,,"A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma","Initial Abstraction Verified Date
                03/14/2018",,,Abstraction Verified No Response,03/14/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00330,"Amgen, Inc.",28076,2,,,"A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, and Efficacy of AMG 592 inAdult Subjects With Steroid Refractory Chronic Graft Versus Host Disease","Initial Abstraction Verified Date
                03/07/2018",,,Abstraction Verified No Response,03/07/2018,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00293,Atara Biotherapeutics,43001403,2,,,"Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab","Initial Abstraction Verified Date
                03/02/2018",,,Abstraction Verified No Response,03/02/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00273,"Odonate Therapeutics, Inc.",87206859,2,,,"A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane","Initial Abstraction Verified Date
                03/01/2018",,,Abstraction Verified No Response,03/01/2018,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00229,"NanOlogy, LLC",56975782,2,,,"Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases","Initial Abstraction Verified Date
                02/23/2018",,,Abstraction Verified No Response,02/23/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2018-00043,Atara Biotherapeutics,43001403,2,,,"Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy","Initial Abstraction Verified Date
                01/26/2018",,,Abstraction Verified No Response,01/26/2018,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-02413,Merck and Company Inc,147288,2,,,A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab With or Without Chemotherapy in Subjects With Advanced Solid Tumors,"Initial Abstraction Verified Date
                01/06/2018",,,Abstraction Verified No Response,01/06/2018,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-01823,Merck and Company Inc,147288,2,,,A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors,"Initial Abstraction Verified Date
                10/11/2017",,,Abstraction Verified No Response,10/11/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-01766,Ludwig Institute for Cancer Research,2166,2,,,"A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers","Initial Abstraction Verified Date
                10/05/2017",,,Abstraction Verified No Response,10/05/2017,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-01648,Apollomics Inc.,89123678,2,,,"Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advance Solid Tumors","Initial Abstraction Verified Date
                09/19/2017",,,Abstraction Verified No Response,09/19/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-01389,Incyte Corporation,109566,2,,,"An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of Parsaclisib in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)","Initial Abstraction Verified Date
                08/10/2017",,,Abstraction Verified No Response,08/10/2017,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-01332,"EMD Serono Research & Development Institute, Inc.",48092613,2,,,"An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors","Initial Abstraction Verified Date
                07/28/2017",,,Abstraction Verified No Response,07/28/2017,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-01165,"Apexigen, Inc.",55374935,2,,,A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma,"Initial Abstraction Verified Date
                08/29/2017",,,Abstraction Verified No Response,08/29/2017,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-01110,Clovis Oncology,30178935,2,,,"TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency","Initial Abstraction Verified Date
                06/29/2017",,,Abstraction Verified No Response,06/29/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-01082,Novartis Pharmaceuticals Corporation,170150,2,,,"BYLieve: A Phase II, Multicenter, Open-label, Three-cohort, Non- Comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After Prior Treatments","Initial Abstraction Verified Date
                07/11/2017",,,Abstraction Verified No Response,07/11/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-01051,"Iovance Biotherapeutics, Inc.",56770754,2,,,"A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma","Initial Abstraction Verified Date
                06/20/2017",,,Abstraction Verified No Response,06/20/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-00885,Ludwig Institute for Cancer Research,2166,2,,,"A Phase 1 Study to Assess Safety and Tolerability of Tremelimumab and Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant (HDT/ASCT)","Initial Abstraction Verified Date
                05/25/2017",,,Abstraction Verified No Response,05/25/2017,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-00774,Abbvie,25971641,2,,,"A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy","Initial Abstraction Verified Date
                05/11/2017",,,Abstraction Verified No Response,05/11/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-00648,"Turning Point Therapeutics, Inc.",89123574,2,,,"A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)","Initial Abstraction Verified Date
                04/27/2017",,,Abstraction Verified No Response,04/27/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-00611,Menarini Group,60252856,2,,,A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia,"Initial Abstraction Verified Date
                04/21/2017",,,Abstraction Verified No Response,04/21/2017,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-00322,Bristol-Myers Squibb,36140,2,,,"Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy","Initial Abstraction Verified Date
                03/09/2017",,,Abstraction Verified No Response,03/09/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-00276,Eli Lilly and Company,119479,2,,,Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen,"Initial Abstraction Verified Date
                04/27/2017",,,Abstraction Verified No Response,04/27/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2017-00230,Sun Pharma Advanced Research Company Limited,23270742,2,,,"A Two-Part Phase 1/2 Study to Determine Safety, Tolerability, Pharmacokinetics, and Activity of K0706, a Novel Tyrosine Kinase Inhibitor (TKI), in Healthy Subjects and in Subjects With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)","Initial Abstraction Verified Date
                02/23/2017",,,Abstraction Verified No Response,02/23/2017,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-01912,"Tolero Pharmaceuticals, Inc.",28859007,2,,,"A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors","Initial Abstraction Verified Date
                12/21/2016",,,Abstraction Verified No Response,12/21/2016,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-01829,Incyte Corporation,109566,2,,,An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,"Initial Abstraction Verified Date
                05/01/2017",,,Abstraction Verified No Response,05/01/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-01828,TG Therapeutics Inc,31042847,2,,,Phase I Study of Ublituximab and Umbralisib in Combination With Targeted Immunotherapy in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT) of CLL,"Initial Abstraction Verified Date
                12/08/2016",,,Abstraction Verified No Response,12/08/2016,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-01507,"Provectus Biopharmaceuticals, Inc.",17508536,2,,,"A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant","Initial Abstraction Verified Date
                10/23/2016",,,Abstraction Verified No Response,10/23/2016,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-01279,Atara Biotherapeutics,43001403,2,,,Expanded Access Protocol for Providing Tabelecleucel to Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies,"Initial Abstraction Verified Date
                08/25/2016",,,Abstraction Verified No Response,08/25/2016,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-01202,Novartis Pharmaceuticals Corporation,170150,2,,,"A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors","Initial Abstraction Verified Date
                08/10/2016",,,Abstraction Verified No Response,08/10/2016,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-01200,CareFusion,9985476,2,,,"Pivotal Multi Center, Randomized, Controlled, Single-Blinded Study Comparing the Silver Nitrate Coated Indwelling Pleural Catheter to the Uncoated PleurX Catheter for the Management of Symptomatic, Recurrent, Malignant Pleural Effusions","Initial Abstraction Verified Date
                01/12/2017",,,Abstraction Verified No Response,01/12/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-00936,Boehringer Ingelheim Pharmaceuticals Inc,35687,2,,,"Phase I/II Open Label, Dose Escalation Trial to Determine the MTD, Safety, PK and Efficacy of Afatinib Monotherapy in Children Aged ?1 Year to <18 Years With Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and/or Other Solid Tumours With Known ErbB Pathway Deregulation Regardless of Tumour Histology","Initial Abstraction Verified Date
                02/27/2017",,,Abstraction Verified No Response,02/27/2017,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-00818,AstraZeneca Pharmaceuticals LP,34899,2,,,A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours,"Initial Abstraction Verified Date
                06/09/2016",,,Abstraction Verified No Response,06/09/2016,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-00599,Incyte Corporation,109566,2,,,"An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata","Initial Abstraction Verified Date
                05/07/2016",,,Abstraction Verified No Response,05/07/2016,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-00598,"Aduro Biotech, Inc.",48498433,2,,,"A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer","Initial Abstraction Verified Date
                05/03/2016",,,Abstraction Verified No Response,05/03/2016,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-00590,Hoffmann-La Roche,90971,2,,,"A Phase Ib/II, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL","Initial Abstraction Verified Date
                05/07/2016",,,Abstraction Verified No Response,05/07/2016,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-00585,ARIAD Pharmaceuticals,30792,2,,,A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer,"Initial Abstraction Verified Date
                05/07/2016",,,Abstraction Verified No Response,05/07/2016,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-00290,MacroGenics Inc,124446,2,,,"A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer","Initial Abstraction Verified Date
                03/11/2016",,,Abstraction Verified No Response,03/11/2016,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-00212,Innate Pharma,14549789,2,,,Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,"Initial Abstraction Verified Date
                03/03/2016",,,Abstraction Verified No Response,03/03/2016,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2016-00129,"Provectus Biopharmaceuticals, Inc.",17508536,2,,,A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma,"Initial Abstraction Verified Date
                02/11/2016",,,Abstraction Verified No Response,02/11/2016,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2015-01960,"miRagen Therapeutics, Inc.",49643646,2,,,"A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias","Initial Abstraction Verified Date
                12/09/2015",,,Abstraction Verified No Response,12/09/2015,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2015-01872,NewLink Genetics Corporation,158357,2,,,A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors,"Trial Summary Report Date
                02/10/2016",,,Abstraction Verified No Response,11/20/2015,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2015-01819,Virginia Commonwealth University/Massey Cancer Center,238148,2,,,African American Cancer Clinical Trial Decisions: Testing Tailored Messages,"Initial Abstraction Verified Date
                11/13/2015",,,Abstraction Verified No Response,11/13/2015,Interventional,,05/01/2017,,,U,ClinicalTrials.gov,,
NCI-2015-01715,Dynavax Technologies,3487223,2,,,"A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SYNERGY-001)","Initial Abstraction Verified Date
                10/21/2015",,,Abstraction Verified No Response,10/21/2015,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2015-01199,Abbvie,25971641,2,,,Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC Protocol 1410-BTG) Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas,"Initial Abstraction Verified Date
                08/05/2015",,,Abstraction Verified No Response,08/05/2015,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2015-00892,"Boston Biomedical, Inc",35175,2,,,A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,"Initial Abstraction Verified Date
                06/21/2015",,,Abstraction Verified No Response,06/21/2015,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2015-00637,"Senhwa Biosciences, Inc.",50087746,2,,,A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma,"Initial Abstraction Verified Date
                05/06/2015",,,Abstraction Verified No Response,05/06/2015,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2015-00611,Incyte Corporation,109566,2,,,"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","Initial Abstraction Verified Date
                05/05/2015",,,Abstraction Verified No Response,05/05/2015,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2015-00239,"Kite, A Gilead Company",60441672,2,,,A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma,"Initial Abstraction Verified Date
                03/05/2015",,,Abstraction Verified No Response,03/05/2015,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2015-00096,Bristol-Myers Squibb,36140,2,,,"Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)","Initial Abstraction Verified Date
                02/06/2015",,,Abstraction Verified No Response,02/06/2015,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2014-02666,Incyte Corporation,109566,2,,,"A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of Parsaclisib and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)","Initial Abstraction Verified Date
                01/17/2015",,,Abstraction Verified No Response,01/17/2015,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2014-02160,Merck and Company Inc,147288,2,,,A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma,"Initial Abstraction Verified Date
                10/30/2014",,,Abstraction Verified No Response,10/30/2014,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2014-02149,Karyopharm Therapeutics Inc,54187152,2,,,Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),"Initial Abstraction Verified Date
                10/29/2014",,,Abstraction Verified No Response,10/29/2014,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2014-01987,"Astellas Pharma Global Development, Inc.",48002713,2,,,A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,"Initial Abstraction Verified Date
                10/02/2014",,,Abstraction Verified No Response,10/02/2014,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2014-01763,Abbvie,25971641,2,,,A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy,"Initial Abstraction Verified Date
                08/21/2014",,,Abstraction Verified No Response,08/21/2014,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2014-01526,MacroGenics Inc,124446,2,,,"A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk MDS","Initial Abstraction Verified Date
                08/15/2014",,,Abstraction Verified No Response,08/15/2014,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2014-00974,Eli Lilly and Company,119479,2,,,"A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors","Initial Abstraction Verified Date
                05/13/2014",,,Abstraction Verified No Response,05/13/2014,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2014-00678,Tesaro Inc,25957265,2,,,"A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients","Initial Abstraction Verified Date
                04/08/2014",,,Abstraction Verified No Response,04/08/2014,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2014-00223,"Millennium Pharmaceuticals, Inc.",138345,2,,,"A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors","Initial Abstraction Verified Date
                03/19/2014",,,Abstraction Verified No Response,03/19/2014,Interventional,,11/01/2018,,,U,ClinicalTrials.gov,,
NCI-2013-02275,Novartis Pharmaceuticals Corporation,170150,2,,,"A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia","Initial Abstraction Verified Date
                12/11/2013",,,Abstraction Verified No Response,12/11/2013,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2013-02234,OncoMed Pharmaceuticals,192780,2,,,A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),"Trial Summary Report Date
                08/13/2014",,,Abstraction Verified No Response,12/04/2013,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2012-02287,Merck and Company Inc,147288,2,,,"A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients","Initial Abstraction Verified Date
                11/21/2012",,,Abstraction Verified No Response,11/21/2012,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2012-01685,Incyte Corporation,109566,2,,,"An Open-Label, Multiple Simon 2-Stage Study of Itacitinib Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)","Initial Abstraction Verified Date
                10/11/2012",,,Abstraction Verified No Response,10/11/2012,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2012-00986,Incyte Corporation,109566,2,,,"A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma","Initial Abstraction Verified Date
                06/19/2012",,,Abstraction Verified Response,06/19/2012,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2012-00694,Bayer Corporation,35145,2,,,"An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors","Trial Summary Report Date
                08/14/2014",,,Abstraction Verified No Response,05/20/2012,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2012-00291,AstraZeneca Pharmaceuticals LP,34899,2,,,"A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD4547 in Patients With Advanced Solid Malignancies","Initial Abstraction Verified Date
                03/22/2012",,,Abstraction Verified No Response,03/22/2012,Interventional,,11/01/2018,,,U,ClinicalTrials.gov,,
NCI-2011-03444,"Genprex, Inc.",53765063,2,,,Phase I/II Clinical Trial Combining TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer,"Trial Summary Report Date
                08/12/2014",,,Abstraction Verified No Response,07/14/2012,Interventional,,03/01/2019,,,U,ClinicalTrials.gov,,
NCI-2011-00278,Merck and Company Inc,147288,2,,,A Phase I Dose Escalation Study of Oral MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors,"On-going Abstraction Verified Date
                07/11/2012",,,Abstraction Verified Response,07/11/2012,Interventional,,01/01/2019,,,U,ClinicalTrials.gov,,
NCI-2010-02109,"Millennium Pharmaceuticals, Inc.",138345,2,,,"A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Patients With Advanced Malignancies","Initial Abstraction Verified Date
                03/20/2012",,,Abstraction Verified No Response,03/20/2012,Interventional,,11/01/2018,,,U,ClinicalTrials.gov,,
NCI-2010-01944,Celgene,48385871,2,,,"A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","Trial Summary Report Date
                09/12/2014",,,Abstraction Verified No Response,09/11/2010,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
NCI-2010-00483,Novartis Pharmaceuticals Corporation,170150,2,,,"A Phase III Multi-center, Open-label, Randomized Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)","Initial Abstraction Verified Date
                10/25/2011",,,Abstraction Verified No Response,10/25/2011,Interventional,,04/01/2019,,,U,ClinicalTrials.gov,,
